Feed SNPHY
SN
Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
$12.03 -4.45% (-$0.56)
1M -5.69%
Market Cap ¥641.6B
P/E Ratio 16.19x
Div. Yield 1.77%
ROE 13.79%
Bulios Fair Price
$17.04
41.6% upside
Current Price
$12.03
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SNPHY is currently undervalued relative to its market price. How does it work?
Valuation
79 /100
Cheap P/E 16.19x
P/FCF 16.51x
EV/EBITDA 8.31x
Growth
58 /100
Stable Rev. growth 3.48%
Book val. growth 0.48%
FCF growth 45.73%
Profitability
78 /100
Strong Gross margin 55.20%
FCF margin 12.57%
Net margin 12.81%
Quality
65 /100
Average ROIC 11.28%
Asset turnover 0.73x
ROE 13.79%
Debt
100 /100
Low Debt/Equity 0.00x
Net debt/EBITDA -1.21x
Current ratio 2.60x
Stability
41 /100
Moderate Beta 0.25x
Profitable years 3
Rev. volatility 4.45%
Ask StockBot about SNPHY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Takeshi Ito
Employees
3,968
Headquarters
Osaka
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
30 NOV
Dividend Payment
Payment date